StreetInsider.com News Articles

FDA approves Viatris eye drop Ryzumvi for presbyopia treatment

Fri, 16 Oct 2026 16:05:14 -0400

Viatris Inc. (Nasdaq: VTRS) announced that the U.S. Food and Drug Administration has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults, according to a company press release dated Oct. 16, 2026.

Ryzumvi was previously approved in the United States for the treatment of pharmacologically-induced mydriasis, and the company claims it is the only commercially available FDA-approved product for that use. The new approval expands the product's indications to include presbyopia, a condition described as the gradual loss of near focusing ability due to aging, typically becoming noticeable in the early to mid-40s.

Viatris stated it is exploring

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Fri, 16 Oct 2026 16:05:00 -0400

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI^®(phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Fri, 16 Oct 2026 16:05:00 -0400

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

The analyst comments "VTRS announced it will acquire PCRX for $1.65B. This is (+) for PCRX but more mixed for VTRS. The deal will be accretive to EBITDA + good synergies w/ meloxicam. But we'd watch out for: (1) Exparel going generic in 2030 (volume limited), but there are 2 PIV filers w/ litigation ongoing. Base case is for moderate erosion beyond 2030, but mgmt still see sig value beyond 2030. (2) NO-PAIN expires Dec 2027 and needs to be renewed. Downgrade

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Form 8-K Viatris Inc For: Oct 08

Thu, 08 Oct 2026 08:38:00 -0400

si-local-file:///var/storage/secattach/20261008/27164430.html

Viatris to acquire Pacira BioSciences for $1.65 billion

Thu, 08 Oct 2026 07:45:31 -0400

Viatris Inc. (NASDAQ: VTRS) has agreed to acquire Pacira BioSciences, Inc. (NASDAQ: PCRX) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, according to a joint press release from the two companies.

The transaction, unanimously approved by the boards of both companies, will be structured as a tender offer for all outstanding shares of Pacira common stock. Any shares not tendered will be acquired through a second-step merger at the same price. The deal is expected to close by the end of 2026, subject to customary closing conditions including a majority tender of Pacira shares and

Viatris to acquire Pacira BioSciences for $1.65 billion

Thu, 08 Oct 2026 07:45:31 -0400

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

Mon, 05 Oct 2026 06:59:00 -0400

PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss results.

Investors and the general public are invited to

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

Mon, 05 Oct 2026 06:59:00 -0400

Investors and the general public are invited to

Viatris (VTRS) PT Raised to $26 at UBS

Mon, 05 Oct 2026 05:42:18 -0400

UBS analyst Ashwani Verma raised the price target on Viatris (NASDAQ: VTRS) to $26.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "VTRS shares have outperformed YTD (+40% vs DRG +7%), but we see further upside for YE26 and into 2027, supported by a handful of catalysts and growth drivers, including China, HRT, fast-acting meloxicam, and the upcoming OPUS readouts. In this note, we highlight the upcoming cenerimod Ph3 readout, which we believe is a significantly underappreciated catalyst. We also believe the HRT business has the potential to contribute meaningful topline growth over a multi-year period. We maintain our

Viatris (VTRS) PT Raised to $26 at UBS

Mon, 05 Oct 2026 05:42:18 -0400

UBS analyst Ashwani Verma raised the price target on Viatris (NASDAQ: VTRS) to $26.00 (from $23.00) while maintaining a Buy rating.

Form 4 Viatris Inc For: Sep 30 Filed by: Groothuis Leo Frans

Fri, 02 Oct 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20261002/27143834.html

Form 4 Viatris Inc For: Sep 30 Filed by: SIMMONS DAVID S

Fri, 02 Oct 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143810.html

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Tue, 29 Sep 2026 14:00:00 -0400

PITTSBURGH, Sept. 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider, and is based on independent employee feedback collected globally, highlighting employee trust, workplace experience and organizational culture at Viatris.

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Tue, 29 Sep 2026 14:00:00 -0400

Viatris sues Novo Nordisk over generic Wegovy patent dispute

Fri, 25 Sep 2026 15:25:50 -0400

Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.

Mylan Pharmaceuticals, a Viatris unit, asked the court Thursday to rule that its generic product would not infringe Novo Nordisk's patent for a method of administering single-dose Wegovy pens for weight loss.

Novo Nordisk generated nearly $31 billion from its semaglutide-based weight loss medications Wegovy and Ozempic last year, according to company reports.

Generic versions of Wegovy and Ozempic cannot enter the U.S. market until 2032, when Novo Nordisk

Viatris sues Novo Nordisk over generic Wegovy patent dispute

Fri, 25 Sep 2026 15:25:50 -0400

Novo Nordisk generated nearly $31 billion from its semaglutide-based weight loss medications Wegovy and Ozempic last year, according to company reports.

Generic versions of Wegovy and Ozempic cannot enter the U.S. market until 2032, when Novo Nordisk

Oppenheimer Starts Viatris (VTRS) at Outperform

Wed, 23 Sep 2026 06:10:13 -0400

(Updated - September 23, 2026 6:10 AM EDT)

Oppenheimer analyst Les Sulewski initiates coverage on Viatris Inc (NASDAQ: VTRS) with a Outperform rating and a price target of $25.00.

The analyst comments "We initiate coverage of Viatris with an Outperform rating as we believe the market continues to value VTRS as a declining generics and established-brands company, overlooking an improving base business, cost savings, and a late-stage pipeline with two potential blockbuster assets. Greater China, new products, and value-added medicines should support revenue growth, while ~$400M of net savings through 2028, improving mix, and share repurchases should drive faster EBITDA and EPS